[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Capital Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":615},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,75,0,25,[9,48,74,101,123,149,172,203,220,247,276,304,324,341,364,391,417,436,462,487,509,526,545,571,589],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100642728","improving-the-reliability-of-llms-as-medical-assistants-for-the-general-public-100642728",false,"NCT07651280","Improving the Reliability of LLMs as Medical Assistants for the General Public","Improving the Reliability of LLMs as Medical Assistants for the General Public: a Proof of Concept Simulation Trial","LAMP-1","Inclusion Criteria:\n\n1. Age 18 years or greater, male or female;\n2. Completed primary school or higher education;\n3. Able to use a smartphone or computer to complete online interaction;\n4. No history of acute ischemic stroke, systemic lupus erythematosus, gastric ulcer, pneumonia, acute cardiac infarction, urinary tract infection, uterine fibroids, diabetes, osteoarthritis, or migraine.\n5. Able to understand and comply with study procedures and to provide written informed consent.\n\nExclusion Criteria:\n\n1. Currently or previously employed as a healthcare worker;\n2. Previously received systematic medical training;\n3. Currently involved in concurrent research that may interfere with the results of the present trial;\n4. The investigator considered that the participant had other conditions that might affect compliance or preclude participation.",true,"ALL","18 Years",{"count":22,"type":23},525,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study will evaluate whether three-minute six-dimensions education(3M-6D education) can improve the reliability of large language models as medical assistants for the general public. Participants will be randomly assigned to receive or not receive 3M-6D education and then use ChatGPT, Gemini, or non-AI information resources. The study will assess relevant condition identification, disposition concordance, red-flag identification, and NASA-TLX score.",[29],"Relevant Conditions Identification",[31,32,33,34],"3M-6D education","Large Language Models","relevant conditions identification","Cognitive Load Theory","NOT_YET_RECRUITING","2026-06-22",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":41,"type":23},"2026-06-20",{"date":43,"type":23},"2026-07-20",{"name":45,"class":46},"Capital Medical University","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":19,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100642146","phase-2-a-study-of-probiotics-in-patients-with-acute-ischemic-stroke-100642146","NCT07651332","A Study of Probiotics in Patients With Acute Ischemic Stroke","Placebo-Controlled, Double-Blind, Phase 2 Trial of Probiotic Supplementation in Acute Ischemic Stroke","PRO-STROKE","Inclusion Criteria:\n\n1. Age ≥ 60 years;\n2. Diagnosis of ischemic stroke; (1)Ischemic stroke is defined as clinically manifest acute neurological deficits linked to an acute cerebral infarct in the anterior circulation; (2)Central retinal artery occlusion or likely central retinal artery occlusion are not considered ischemic strokes in the context of this trial;\n3. Randomization within 72 hours of symptom onset;\n4. Ability to provide written informed consent;\n5. Baseline NIHSS \\>=4;\n6. Pre-stroke mRS \\\u003C=2;\n\nExclusion Criteria:\n\n1. Suspected lack of compliance;\n2. Presence of moderate to severe dysphagia;\n3. Current participation in other interventional trials or recent participation (within the last 30 days) in an interventional trial;\n4. Known allergy or hypersensitivity to trial compounds components or placebo;\n5. No known history before randomization of imminently life-shortening medical conditions or any other reason, including any physical, psychological, or psychiatric condition that in the investigator's opinion would compromise the safety or interfere with the subject's participation in this study, or would make the subject an unsuitable candidate to receive study drug, or would put the subject at risk by participating in the study;\n6. Malignant diseases including active malignancies with a life expectancy of less than 3 months;\n7. Major gastro-intestinal (GI) surgery, chronic inflammatory diseases of the gut and significant GI-neoplasms;","60 Years",{"count":58,"type":23},220,[60],"PHASE2","The primary objective of this study is to evaluate the effect of daily oral administration of the probiotic supplement OMNi-BiOTiC® SR-9 for 90 days, compared to placebo, on gut microbiome beta diversity in patients aged 60 years or older with acute ischemic stroke.",[63],"Ischemic Stroke",[65],"ischemic stroke","2026-06-16",{"date":68,"type":39},"2026-06-17",{"date":70,"type":23},"2026-09-01",{"date":72,"type":23},"2027-12-31",{"name":45,"class":46},{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":47},"100641638","cerebrospinal-fluid-mitochondrial-biomarkers-in-ischemic-stroke-and-alzheimer-disease-100641638","NCT07600996","Cerebrospinal Fluid Mitochondrial Biomarkers in Ischemic Stroke and Alzheimer Disease","A Prospective Observational Study of Cerebrospinal Fluid Mitochondrial Biomarkers Measured by Flow Cytometry in Patients With Ischemic Stroke and Alzheimer Disease Controls","Inclusion Criteria:\n\n* Age 18 years or older. Patients treated at Xuanwu Hospital, Capital Medical University between March 2026 and May 2026.\n\nDiagnosis of ischemic stroke or Alzheimer disease according to standard clinical diagnostic criteria.\n\nDiagnostic lumbar puncture performed for clinical indications as part of routine medical care.\n\nAvailability of residual cerebrospinal fluid after completion of clinically required testing.\n\nAbility to provide written informed consent, or availability of a legally authorized representative to provide consent when appropriate.\n\nFor ischemic stroke patients, availability of baseline neurological assessment and planned follow-up for 90-day modified Rankin Scale assessment.\n\nExclusion Criteria:\n\n* Lumbar puncture performed solely for research purposes rather than clinical indication.\n\nInsufficient residual cerebrospinal fluid volume for research flow cytometry analysis.\n\nGrossly bloody or severely contaminated cerebrospinal fluid sample that precludes reliable flow cytometry analysis.\n\nKnown central nervous system infection, malignant meningitis, or other inflammatory or neoplastic condition that, in the investigator's judgment, may substantially confound cerebrospinal fluid mitochondrial measurements.\n\nInability to obtain informed consent from the participant or legally authorized representative.\n\nMissing key clinical outcome data, including admission NIHSS, discharge NIHSS, or planned 90-day mRS follow-up for ischemic stroke participants.\n\nAny condition judged by the investigator to make the participant unsuitable for inclusion in the study.",{"count":82,"type":23},40,"OBSERVATIONAL","This prospective observational study aims to investigate cerebrospinal fluid mitochondrial biomarkers in patients with ischemic stroke and Alzheimer disease controls who undergo diagnostic lumbar puncture for clinical indications at Xuanwu Hospital, Capital Medical University.\n\nResidual cerebrospinal fluid samples will be analyzed by flow cytometry to quantify mitochondrial content, mitochondrial membrane potential, and cellular or vesicular source-related markers. The flow cytometry panel will include MitoTracker, JC-1, and membrane-associated markers including CD45, CD41, CD24, vWF, and EAAT1.\n\nIn patients with ischemic stroke, the study will further examine whether cerebrospinal fluid mitochondrial measurements are associated with neurological severity and functional outcomes, including admission and discharge NIHSS scores and the 90-day modified Rankin Scale score. Alzheimer disease patients undergoing diagnostic lumbar puncture will serve as disease controls for biomarker comparison.",[63,86],"Alzheimer Disease (AD)",[88,89,90,91,92],"Cerebrospinal fluid","Mitochondria","MitoTracker","NIHSS","Stroke outcome","RECRUITING","2026-06-14",{"date":66,"type":39},{"date":97,"type":39},"2026-03-01",{"date":99,"type":23},"2026-08-30",{"name":45,"class":46},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":24,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":47},"100641593","phase-1-in10018-in-combination-with-dalpiciclib-for-progressive-meningiomas-100641593","NCT07652762","IN10018 in Combination With Dalpiciclib for Progressive Meningiomas","An Open-Label Phase Ib Clinical Study Evaluating the Safety, Tolerability, and Efficacy of IN10018 in Combination With Dalpiciclib in Participants With Progressive Meningiomas","Inclusion Criteria:\n\nInclusion Criteria:\n\nParticipants must be able to understand and willing to sign a written informed consent form and agree to comply with all study requirements. Written informed consent must be obtained before any study-related examination or procedure is performed.\n\nAged 18 years or older, male or female.\n\nHistologically confirmed meningioma meeting at least one of the following conditions:\n\n1. World Health Organization (WHO) Grade 2 or Grade 3 meningioma; or\n2. WHO Grade 1 meningioma that has recurred after surgery or radiotherapy and demonstrates clear radiographic or clinical progression, as determined by the investigator.\n\nNo available standard treatment option, or failure of standard treatment, including surgery, radiotherapy, or other systemic therapy.\n\nAt least 24 weeks must have elapsed since completion of radiotherapy, including external beam radiation therapy, brachytherapy, or radiosurgery such as Gamma Knife or CyberKnife.\n\nAt least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), as confirmed by the investigator.\n\nEastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. Estimated life expectancy of at least 3 months, as determined by the investigator.\n\nAdverse effects caused by previous treatments must have recovered to Grade 1 or lower according to the Common Terminology Criteria for Adverse Events (CTCAE), except for alopecia and fatigue.\n\nThe dose of corticosteroids or other hormonal treatment must have been stable for at least 4 days before enrollment.\n\nAdequate hematologic and organ function, based on laboratory tests performed within 7 days before the first dose, as follows:\n\nHematologic function:\n\n1. Hemoglobin of at least 100 g\u002FL, without dependence on red blood cell transfusion or erythropoietin.\n2. Platelet count of at least 100 × 10\\^9\u002FL, without dependence on platelet transfusion.\n3. Absolute neutrophil count of at least 1.5 × 10\\^9\u002FL, without the use of colony-stimulating factors.\n\n   Hepatic function:\n4. Total bilirubin no greater than the upper limit of normal.\n5. Alanine aminotransferase and aspartate aminotransferase no greater than 2.5 times the upper limit of normal.\n\n   Renal function:\n6. Serum creatinine no greater than 1.5 times the upper limit of normal.\n7. Either creatinine clearance calculated using the Cockcroft-Gault formula of at least 60 mL\u002Fmin or estimated glomerular filtration rate calculated using the Modification of Diet in Renal Disease formula of at least 60 mL\u002Fmin\u002F1.73 m².\n\n   Urinary protein and coagulation function:\n8. Urine protein negative or trace. Participants with urine protein of 1+ must have a morning spot urine protein-to-creatinine ratio of less than 0.5 or 24-hour urinary protein of less than 0.5 g\u002F24 hours.\n9. International normalized ratio no greater than 1.5 and activated partial thromboplastin time no greater than 1.5 times the upper limit of normal.\n\nFemale participants must not be pregnant or breastfeeding and must meet one of the following conditions:\n\n1. Not be a woman of childbearing potential; or\n2. If a woman of childbearing potential, agree to follow the protocol-specified contraceptive requirements during study treatment and for 3 months after the last dose.\n\nExclusion Criteria:\n\nMajor surgery or major trauma within 28 days before the first dose, or diagnostic biopsy within 14 days before the first dose.\n\nReceipt of systemic anticancer treatment, including an investigational drug, within the protocol-specified washout period, including chemotherapy or targeted therapy within 14 days or 5 half-lives before the first dose, whichever is shorter, or immunotherapy within 28 days before the first dose.\n\nPrevious treatment with a focal adhesion kinase inhibitor or a cyclin-dependent kinase 4\u002F6 inhibitor, including dalpiciclib.\n\nA serious cardiovascular event or clinically significant cardiovascular condition within 6 months before initiation of study treatment, including but not limited to:\n\n1. Left ventricular ejection fraction below 50%;\n2. Corrected QT interval greater than 480 milliseconds;\n3. New York Heart Association functional class 2 or higher;\n4. History of serious arrhythmia or cardiomyopathy. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage. Participants with small-volume effusions detectable only by imaging may be considered eligible.\n\nMalabsorption syndrome or inability to take oral medication. Serious gastrointestinal disease, including uncontrolled inflammatory gastrointestinal disease, active Crohn disease, active ulcerative colitis, or uncontrolled gastrointestinal bleeding.\n\nActive infection that is not adequately controlled by systemic treatment. Known human immunodeficiency virus infection. Human immunodeficiency virus testing is not required during screening unless mandated by local regulations or institutional policy.\n\nKnown active hepatitis B virus or hepatitis C virus infection. Hepatitis B virus and hepatitis C virus testing is not required during screening unless mandated by local regulations or institutional policy.\n\nAny medical history, treatment, laboratory abnormality, or other condition that, in the investigator's judgment, could confound interpretation of the study results, interfere with participant compliance, or compromise the participant's safety or interests.\n\nKnown psychiatric illness or substance abuse that could interfere with compliance with study requirements.\n\nKnown hypersensitivity to IN10018, dalpiciclib, or any component of either study drug.\n\nSystemic treatment with a strong inhibitor or inducer of CYP3A4, CYP2D6, or P-glycoprotein within 14 days before the first dose, or anticipated need for such treatment during the study treatment period.",{"count":109,"type":23},24,[111],"PHASE1","This open-label Phase Ib study will evaluate the safety, tolerability, and preliminary effectiveness of IN10018 in combination with dalpiciclib in adults with progressive meningiomas. Progressive meningiomas are tumors arising from the membranes surrounding the brain that have continued to grow or have returned after previous treatment.\n\nParticipants will receive both study drugs by mouth in 28-day treatment cycles. IN10018 will be taken once daily throughout each cycle, and dalpiciclib will be taken once daily for 21 days followed by 7 days without dalpiciclib. Treatment may continue until the tumor progresses, unacceptable side effects occur, or another reason for stopping treatment applies.\n\nThe study includes a dose-confirmation phase and a dose-expansion phase. The main goals are to evaluate side effects and determine a recommended dose of the combination for further study. Researchers will also assess whether the treatment can shrink tumors or delay tumor growth, measure how the drugs are processed in the body, and explore tumor and blood biomarkers that may be associated with treatment response.",[114,115],"Meningioma","CDK4\u002F6 Inhibitor","2026-06-11",{"date":68,"type":39},{"date":119,"type":23},"2026-06",{"date":121,"type":23},"2029-08",{"name":45,"class":46},{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":133,"conditions":134,"keywords":137,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100642349","clinical-study-on-a-new-diagnostic-strategy-for-osteoporosis-and-sarcopenia-in-chronic-kidney-disease-patients-based-on-mri-ff-100642349","NCT07645794","Clinical Study on a New Diagnostic Strategy for Osteoporosis and Sarcopenia in Chronic Kidney Disease Patients Based on MRI-FF","A Clinical Study on Establishing a New Diagnostic Strategy for Osteoporosis and Sarcopenia in Patients With Chronic Kidney Disease Based on MRI-FFR","Inclusion Criteria:\n\n1. Age between 18 and 80 years old.\n2. Able to understand and sign the informed consent form.\n3. Able to complete MRI-FF scans of the lumbar spine and thigh.\n4. For CKD group: Confirmed diagnosis of chronic kidney disease (eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m² for ≥3 months).\n5. For control group: No history of chronic kidney disease and normal renal function.\n\nExclusion Criteria:\n\n1. Contraindications to MRI (e.g., pacemaker, metal implants, severe claustrophobia).\n2. History of primary bone metabolic disorders (e.g., osteoporosis, hyperparathyroidism) unrelated to CKD.\n3. Current use of anti-osteoporotic drugs (e.g., bisphosphonates, teriparatide).\n4. Severe lower limb deformity or amputation affecting thigh muscle assessment.\n5. Inability to cooperate with the scan due to cognitive impairment or severe illness.","80 Years",{"count":132,"type":23},868,"This is a single-center, observational cohort study aiming to validate the diagnostic value of MRI-FF in identifying osteoporosis and sarcopenia in patients with chronic kidney disease (CKD). A total of 868 participants, including 434 CKD patients and 434 non-CKD controls, will be enrolled at Beijing Jishuitan Hospital. All subjects will undergo MRI-FF scans of the lumbar spine and thigh to assess bone mineral density and muscle fat fraction. The primary objective is to evaluate the correlation between MRI-FF parameters and conventional diagnostic criteria for osteoporosis and sarcopenia, as well as to determine the optimal cut-off values for early detection. The study duration is from March 2026 to December 2028.",[135,136],"Chronic Kidney Disease","Osteoporosis",[135,136,138,139,140,141],"Sarcopenia","MRI-FF","Bone Mineral Density","Muscle Fat Fraction","2026-06-09",{"date":144,"type":39},"2026-06-12",{"date":119,"type":23},{"date":147,"type":23},"2028-12",{"name":45,"class":46},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":24,"phases":158,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":169,"leadSponsor":170,"locationsCount":171},"100643617","domain-specific-large-language-model-assistance-for-emergency-neurological-diagnosis-and-treatmentdemand-100643617","NCT07626229","Domain-Specific Large Language Model Assistance for Emergency Neurological Diagnosis and Treatment（DEMAND）","Domain-Specific Large Language Model Assistance for Emergency Neurological Diagnosis and Treatment: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥18 years;\n* Presentation to the emergency neurology service with acute neurological symptoms;\n* Written informed consent provided by the patient or a legally authorized representative.\n\nExclusion Criteria:\n\n* Presentation primarily for trauma;\n* Pregnancy;\n* Requiring immediate life-saving interventions;\n* Estimated life expectancy of less than 30 days;\n* Participation in another clinical trial within the previous 30 days or in a trial that could interfere with the study or outcome assessment;\n* Any condition that, in the opinion of the investigators, would interfere with the conduct of the trial or the interpretation of the results.",{"count":157,"type":23},1360,[26],"This study will evaluate whether Xuanwu-NeuroAid 2.0, a large language model for emergency neurology, can improve 30-day diagnostic quality in adults with acute neurological symptoms. Physicians will be randomly assigned to AI-assisted care or usual care. In the AI-assisted group, the model will provide diagnostic and management suggestions, while physicians will make all final clinical decisions. The usual-care group will receive standard emergency neurology care without large language model assistance.",[161],"Nervous System Diseases",[163,164,165,166],"Large Language Model","Emergency Neurology","Diagnostic","Acute Neurological Symptoms",{"date":116,"type":39},{"date":142,"type":39},{"date":99,"type":23},{"name":45,"class":46},3,{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":181,"conditions":182,"keywords":186,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":47},"100356308","cerebral-venous-thrombosis-cohort-study-in-china-mainland-100356308","NCT03919305","Cerebral Venous Thrombosis Cohort Study in China Mainland","CCC","Inclusion Criteria:\n\n• Cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis diagnosed by digital subtraction angiography (DSA), magnetic resonance venography (MRV), computed tomography venography (CTV) or high-resolution magnetic resonance imaging (HR-MRI).\n\nExclusion Criteria:\n\n• None of the patient, trustee or immediate family members signed the informed consent.",{"count":180,"type":23},3000,"This study was aimed to reveal the clinical features,natural history of the diseases and current therapeutic situations of cerebral venous thrombosis (CVT) in China mainland. Blood samples and cerebrospinal fluid samples will be collected after recruitment to reveal the pathological mechanisms of CVT and identify the biomarkers for CVT.",[183,184,185],"Cerebral Venous Sinus Thrombosis","Deep Cerebral Vein Thrombosis","Cortical Vein Thrombosis",[187,188,189,190,191,192,193,194],"Cerebral venous sinus thrombosis","Deep cerebral vein thrombosis","Cortical vein thrombosis","Cohort study","Real world evidence","Observational study","China mainland","Cerebral venous system thrombosis","2026-05-29",{"date":197,"type":39},"2026-06-02",{"date":199,"type":39},"2019-01-01",{"date":201,"type":23},"2026-12-31",{"name":45,"class":46},{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":56,"enrollmentInfo":209,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":4},"100638951","development-and-evaluation-of-an-intelligent-diagnosis-system-for-dry-eye-disease-based-on-confocal-microscopy-100638951","NCT07614347","Development and Evaluation of an Intelligent Diagnosis System for Dry Eye Disease Based on Confocal Microscopy","Inclusion Criteria:\n\nNormal group:\n\n1. Healthy adults aged 18 to 60;\n2. OSDI score of ocular surface disease Index \\\u003C13 points;\n3. Good tear film stability (tear film break-up time TBUT≥10 seconds) and negative corneal fluorescein staining;\n\nDry eye Group:\n\n1. Healthy adults aged 18 to 60;\n2. Tear film break-up time ≤5 seconds or SchirmerⅠ≤5mm\u002F5min without surface anesthesia, with one of the subjective symptoms such as dryness, foreign body sensation, burning sensation, fatigue, discomfort, or vision fluctuation in the eyes;\n3. 5 \\\u003CTear film break-up time ≤10 seconds or 5mm\u002F5 min\u002Fless under no surface anesthesia; When SchirmerⅠ is ≤10 mm\u002F5min, there is one of the subjective symptoms in the eyes, such as dryness, foreign body sensation, burning sensation, fatigue, discomfort, and vision fluctuation. At the same time, the fluorescein staining of the cornea and conjunctiva is positive.\n\nExclusion Criteria:\n\n1. Combined with systemic diseases or neurological diseases that may affect corneal nerve function;\n2. Having used any local anti-inflammatory drugs for the eyes within 2 weeks before enrollment or having a history of wearing contact lenses within 3 months;\n3. Other eye diseases besides dry eye and history of eye surgery;",{"count":5,"type":23},"Dry eye disease is a major ophthalmic health issue that severely affects the visual function and quality of life of the national population. Its core pathological mechanism involves a vicious cycle of ocular surface inflammation and neural abnormalities; however, clinical practice still lacks an objective and quantitative gold standard for diagnosis. Although in vivo confocal microscopy (IVCM) enables cellular-level, in vivo observation of the ocular surface, image analysis remains heavily dependent on manual interpretation, highlighting an urgent need for an intelligent quantitative framework.This project aims to construct a high-quality, standardized ocular surface imaging database and develop a high-precision deep learning algorithm to achieve accurate segmentation and quantification of corneal nerves (including both whorl-like and linear patterns) and inflammatory cells, and to validate their associations with clinical indicators of dry eye disease. The ultimate goal is to develop and evaluate an IVCM-based multimodal intelligent diagnostic system for dry eye, transforming IVCM from an observational tool into an intelligent decision-support system, with real-world performance validated through an independent prospective cohort.This project is expected to establish a multimodal AI diagnostic model for dry eye, create a standardized computational framework for imaging biomarkers, and enable a paradigm shift from qualitative description to quantitative diagnosis. The findings will provide reliable decision-making support for precision subtyping and personalized treatment of dry eye disease, advancing ophthalmic practice toward a data-driven, intelligent paradigm.",[212],"Dry Eye","2026-05-26",{"date":195,"type":39},{"date":216,"type":23},"2026-06-01",{"date":218,"type":23},"2028-12-31",{"name":45,"class":46},{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":130,"enrollmentInfo":228,"targetDuration":4,"studyType":24,"phases":230,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":246},"100632403","phase-1-anisodine-hydrobromide-for-patients-with-acute-ischemic-stroke-undergoing-endovascular-therapy-heal-100632403","NCT07513233","Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL)","Safety and Efficacy of Anisodine Hydrobromide in Patients With Ischemic Stroke Undergoing Endovascular Treatment","HEAL","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Imaging-confirmed anterior-circulation large-vessel occlusion involving the intracranial internal carotid artery, the middle cerebral artery M1 segment, or the proximal M2 segment or a dominant M2 branch. A dominant M2 branch was defined as an M2 branch supplying ≥50% of the middle cerebral artery territory.\n* Eligible for and planned to undergo endovascular treatment (EVT) within 24 hours according to current clinical practice.\n* National Institutes of Health Stroke Scale (NIHSS) score ≥6 at baseline.\n* Alberta Stroke Program Early CT Score (ASPECTS) ≥6 on baseline noncontrast CT.\n* Pre-stroke modified Rankin Scale (mRS) score of 0 to 1.\n* Provision of written informed consent by the participant or the participant's legally authorized representative.\n\nExclusion Criteria:\n\n* Evidence of intracranial hemorrhagic disease on head CT, including hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage.\n* History of congenital or acquired bleeding disorders, coagulation factor deficiency, thrombocytopenic disorders, or other clinically significant hemorrhagic conditions.\n* Vascular anatomy expected to preclude successful endovascular treatment because of excessive tortuosity or other technical reasons.\n* Known allergy to iodinated contrast agents.\n* Pregnant or breastfeeding women, or women planning pregnancy during the study period or within 90 days after enrollment.\n* Known hypersensitivity to anisodine hydrobromide or a history of severe intolerance after prior exposure.\n* Presence of clinical conditions that may be worsened by anticholinergic drugs, including but not limited to angle-closure glaucoma, urinary retention or benign prostatic hyperplasia with dysuria, or paralytic ileus.\n* Severe arrhythmia or hemodynamic instability, including but not limited to tachyarrhythmia requiring cardioversion, recurrent syncope due to arrhythmia, vasopressor-dependent hypotension, or persistent hypotension.\n* Severe psychiatric disorder, dementia, or impaired consciousness that would preclude informed consent or protocol-required follow-up.\n* Malignant tumor or other severe systemic disease with an expected survival of less than 90 days.\n* Participation in another interventional clinical study within 30 days before enrollment, or current participation in another interventional clinical study.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.",{"count":229,"type":23},92,[111],"This study is an investigator-initiated Phase 1b clinical trial employing an open-label, non-randomized, dose-escalation design. The primary objective is to evaluate the safety and tolerability of the investigational intervention and to determine the recommended dose for subsequent clinical studies.",[233],"Acute Ischemic Stroke",[235,236,237],"Endovascular Treatment","Neuroprotection","Stroke","2026-05-17",{"date":240,"type":39},"2026-05-19",{"date":242,"type":39},"2026-04-28",{"date":244,"type":23},"2026-10-30",{"name":45,"class":46},2,{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":24,"phases":257,"briefSummary":259,"conditions":260,"keywords":261,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":275},"100632127","phase-3-efficacy-and-safety-of-interleukin-6-receptor-inhibitor-combined-with-endovascular-treatment-in-patients-with-acute-posterior-circulation-large-vessel-occlusion-stroke-100632127","NCT07509645","Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke","Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-3","IRIS-3","Inclusion Criteria:\n\n1. Age 18 years or older, of either sex;\n2. Acute ischemic stroke caused by occlusion of the basilar artery;\n3. Decide to undergo emergency endovascular treatment;\n4. Time from stroke onset to groin puncture within 24 hours;\n5. National Institutes of Health Stroke Scale (NIHSS) ≥ 10;\n6. Posterior circulation Alberta Stroke Program Early computed tomography score (pc-ASPECTS) ≥ 6;\n7. Signed informed consent from the patients or the legally authorized representatives.\n\nExclusion Criteria:\n\n1. Intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage;\n2. Pre-stroke modified Rankin scale (mRS) score \\>1;\n3. Known allergy to tocilizumab or excipients;\n4. Known allergy to iodinated contrast agents;\n5. Anticipated difficulty in completing endovascular treatment due to vascular tortuosity;\n6. History of congenital or acquired bleeding disorders, coagulation factor deficiency diseases, or thrombocytopenic diseases;\n7. Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg despite blood pressure control;\n8. Neutrophils \\\u003C 2 × 10\\^9 \u002FL;\n9. Platelets \\\u003C 100 × 10\\^9 \u002FL;\n10. Blood glucose \\\u003C2.8 mmol\u002FL (50 mg\u002FdL) or \\>22.2 mmol\u002FL (400 mg\u002FdL);\n11. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \\>2 times the upper limit of normal;\n12. Known recent or current serum creatinine \\>2 times the upper limit of normal or estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin;\n13. Pregnant, lactating, or planning pregnancy within 90 days;\n14. Severe mental disorders or inability to comply with informed consent and follow-up requirements due to dementia;\n15. Concurrent malignant tumors or severe systemic diseases with expected survival of less than 90 days;\n16. Presence of autoimmune diseases or use of immunosuppressive drugs;\n17. Systemic infectious diseases;\n18. Participation in another interventional clinical study within 30 days before randomization or currently participating in another interventional clinical study;\n19. Any circumstance that, as assessed by the investigators, might result in harm to the patients if study therapy is initiated;\n20. Other conditions that the investigator considers might affect compliance or preclude participation in this study.",{"count":256,"type":23},348,[258],"PHASE3","This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.",[63],[262,263,264,265,266],"large vessel occlusion","endovascular treatment","posterior circulation","interleukin-6 inhibitor","neuroprotection","2026-04-29",{"date":269,"type":39},"2026-05-05",{"date":271,"type":39},"2026-04-22",{"date":273,"type":23},"2027-04-20",{"name":45,"class":46},13,{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":24,"phases":286,"briefSummary":287,"conditions":288,"keywords":292,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":47},"100621605","eit-guided-respiratory-physiotherapy-for-prolonged-mechanical-ventilation-pmv-100621605","NCT07372794","EIT-Guided Respiratory Physiotherapy for Prolonged Mechanical Ventilation (PMV)","Electrical Impedance Tomography-Guided Respiratory Physiotherapy for Liberation From Prolonged Mechanical Ventilation: A Multicenter Randomized Controlled Trial","PMV","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Invasive mechanical ventilation for ≥ 21 consecutive days.\n* Clinically stable and eligible for respiratory physiotherapy as determined by the treating team.\n* Expected to remain on invasive mechanical ventilation for at least 48 hours after enrollment.\n* Written informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n* Contraindications to electrical impedance tomography .\n* Hemodynamic instability requiring high-dose vasoactive support.\n* Severe hypoxemia refractory to optimization.\n* Unstable fractures or other contraindications to mobilization or positioning.\n* Pregnancy.\n* Expected death within 48 hours.",{"count":285,"type":23},200,[26],"Patients with prolonged mechanical ventilation (PMV) frequently experience impaired ventilation distribution, respiratory muscle dysfunction, secretion retention, and delayed liberation from mechanical ventilation. Electrical impedance tomography (EIT) provides real-time bedside visualization of regional ventilation and enables individualized respiratory physiotherapy strategies.\n\nThis multicenter randomized controlled trial aims to evaluate whether EIT-guided respiratory physiotherapy improves ventilator-free days at day 28 compared with conventional respiratory physiotherapy in adult patients with PMV.\n\nRespiratory physiotherapy consists of airway clearance, chest physiotherapy techniques, breathing pattern optimization, and therapeutic positioning. In the EIT-guided group, real-time EIT imaging is used to individualize physiotherapy strategies based on predefined ventilation distribution indicators, while the control group receives standardized physiotherapy according to institutional protocols without EIT guidance.\n\nSecondary outcomes include successful liberation from mechanical ventilation, diaphragm ultrasound parameters, EIT-derived ventilation distribution indices (exploratory mechanistic outcomes), ICU Mobility Scale, healthcare resource utilization, and safety outcomes.",[289,290,291],"Prolonged Mechanical Ventilation","Respiratory Failure","Critical Illness",[293,289,294,295,296],"Electrical Impedance Tomography","Respiratory Physiotherapy","Ventilator Weaning","Ventilator-Free Days",{"date":298,"type":39},"2026-05-04",{"date":300,"type":39},"2026-02-16",{"date":302,"type":23},"2026-12-15",{"name":45,"class":46},{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":24,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":4},"100636190","phase-3-remote-ischemic-conditioning-for-high-altitude-polycythemia-in-high-altitude-immigrant-populations-100636190","NCT07562464","Remote Ischemic Conditioning for High Altitude Polycythemia in High-Altitude Immigrant Populations","Inclusion Criteria:\n\nAged ≥18 years, of either sex; Continuous residence in a high-altitude region (≥2500 meters) for more than 6 months, with no plan for long-term departure from the plateau during the study period; Meeting the diagnostic criteria for high-altitude polycythemia; Willing to provide written informed consent.\n\nExclusion Criteria:\n\nOther hematologic diseases, such as anemia or abnormal leukocytosis; Severe dysfunction of vital organs (e.g., heart, liver, kidney, lungs); Active malignancy, uncontrolled hyperthyroidism, active autoimmune disease, or poorly controlled diabetes mellitus; Pregnancy, planned pregnancy, or lactation for female participants; Contraindications to RIC (e.g., severe peripheral arterial disease, venous thrombosis, or soft tissue injury in the upper limbs); Any other condition deemed by the investigator to be unsuitable for participation in the study.",{"count":311,"type":23},222,[258],"This study is a multicenter, prospective, randomized, open-label, parallel-controlled clinical trial. The participants are adult patients with high-altitude polycythemia who have been long-term residents (for \\>6 months) in regions at an altitude of ≥2500 meters. Participants are randomly assigned to one of two groups: a conventional medication group and a remote ischemic conditioning (RIC) intervention group. The study aims to evaluate the effectiveness of a standardized 90-day RIC intervention, as an add-on to conventional medication, in managing high-altitude polycythemia.",[315],"High Altitude Polycythemia","2026-04-25",{"date":318,"type":39},"2026-05-01",{"date":320,"type":23},"2026-05-20",{"date":322,"type":23},"2028-06-30",{"name":45,"class":46},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":56,"enrollmentInfo":330,"targetDuration":4,"studyType":24,"phases":332,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":340,"locationsCount":4},"100636191","phase-3-efficacy-of-remote-ischemic-conditioning-for-hypertension-in-high-altitude-immigrant-populations-100636191","NCT07562477","Efficacy of Remote Ischemic Conditioning for Hypertension in High-Altitude Immigrant Populations","Inclusion Criteria:\n\nAge 18-60 years, of either sex; Continuous residence in a high-altitude region (\\>2500 m) for more than 6 months, with no plan for long-term departure from the plateau during the study period; Meeting the diagnostic criteria for essential hypertension; Willing to provide written informed consent.\n\nExclusion Criteria:\n\nEvidence of secondary hypertension; Severe dysfunction of vital organs (e.g., heart, liver, kidney, lungs); Active malignancy, uncontrolled hyperthyroidism, active autoimmune disease, or poorly controlled diabetes mellitus; Office blood pressure ≥180\u002F110 mmHg, or 24-hour average blood pressure ≥170\u002F100 mmHg; Hospitalization for hypertensive crisis or emergency at least once within the past 3 months; History of cardiovascular or cerebrovascular event within the past 3 months; Pregnancy, planned pregnancy, or lactation for female participants; Contraindications to RIC (e.g., severe peripheral arterial disease, venous thrombosis, or soft tissue injury in the upper limbs); Any other condition deemed by the investigator to be unsuitable for participation in the study.",{"count":331,"type":23},184,[258],"This study is a multicenter, prospective, randomized, open-label, parallel-controlled clinical trial. The study participants are adult patients with hypertension who have been long-term residents (for \\>6 months) in high-altitude regions (≥2500 m). They are randomly assigned to one of two groups: a conventional medication group and a remote ischemic conditioning (RIC) intervention group. The study aims to evaluate the effectiveness of a standardized 30-day RIC intervention, as an add-on to conventional antihypertensive medication, for reducing blood pressure in hypertensive immigrants living at high altitude.",[335],"Hypertension",{"date":318,"type":39},{"date":338,"type":23},"2026-05-10",{"date":322,"type":23},{"name":45,"class":46},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":19,"minAge":347,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":24,"phases":349,"briefSummary":350,"conditions":351,"keywords":353,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":47},"100636030","effects-of-music-therapy-on-anxiety-symptoms-in-patients-with-prolonged-mechanical-ventilation-a-randomized-controlled-trial-100636030","NCT07560384","Effects of Music Therapy on Anxiety Symptoms in Patients With Prolonged Mechanical Ventilation: A Randomized Controlled Trial","Inclusion Criteria:\n\n\\- 1、Age \\> 50 years 2、Diagnosed with Prolonged Mechanical Ventilation (PMV), meeting the following criteria: Continuous mechanical ventilation for ≥ 21 days Daily mechanical ventilation duration ≥ 6 hours Ventilation via endotracheal tube, tracheostomy, or non-invasive interface (face\u002Fnasal mask).\n\n3、Voluntarily signed the informed consent form (either by the patient or their legal representative).\n\nExclusion Criteria:\n\n* 1、Cognitive or psychiatric disorders: history of severe mental illness (e.g., schizophrenia, severe depression, bipolar disorder) or diagnosed moderate-to-severe dementia\u002Fcognitive impairment.\n\n  2、Presence of delirium: assessed as positive by the Confusion Assessment Method for the ICU (CAM-ICU) prior to enrollment.\n\n  3、Extreme hemodynamic instability: unstable vital signs requiring frequent resuscitation, or in the acute phase of a severe cardio-cerebrovascular accident.\n\n  4、Untreated hearing impairment. 5、Physical conditions preventing safe earphone use (e.g., skin damage, burns, facial or cranial fractures).\n\n  6、Poor prognosis: end-stage disease or assessed by the investigator as having a life expectancy insufficient to complete the intervention and follow-up period.","50 Years",{"count":285,"type":23},[26],"The purpose of this study is to evaluate the effects of music therapy on anxiety symptoms in patients requiring prolonged mechanical ventilation (PMV). PMV patients, defined as those ventilated for more than 21 days, often experience intense psychological stress and anxiety due to long-term intubation and the ICU environment. High anxiety can lead to \"patient-ventilator asynchrony,\" which delays the weaning process.\n\nIn this study, 200 participants will be randomly assigned to either a control group receiving standard care or an experimental group receiving patient-directed music therapy. The music therapy intervention involves listening to selected music through noise-canceling headphones for 30 minutes, twice daily, over a 14-day period. The study will measure improvements in anxiety levels, pain, and sleep quality to determine if music therapy can help break the cycle of anxiety and facilitate recovery.",[352,289],"Anxiety",[354,289,352,355,356],"Music Therapy","Intensive Care Unit","Patient-Directed Music Intervention","2026-04-24",{"date":318,"type":39},{"date":360,"type":23},"2026-05",{"date":362,"type":23},"2027-05",{"name":45,"class":46},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":347,"enrollmentInfo":371,"targetDuration":4,"studyType":24,"phases":373,"briefSummary":374,"conditions":375,"keywords":378,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":47},"100614078","stereotactic-radiotherapy-treatment-for-treatment-resistant-depression-100614078","NCT07274917","Stereotactic Radiotherapy Treatment for Treatment-resistant Depression","The Efficacy and Safety of Stereotactic Radiotherapy for Treatment-Resistant Depression: An Open-Label Exploratory Study","Inclusion Criteria:\n\n* Outpatients or inpatients aged 18 to 50 years (inclusive), regardless of gender.\n* Meet the diagnostic criteria for Major Depressive Disorder (MDD), recurrent, without psychotic features, as defined by The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).\n* Documented treatment-resistant depression, defined as a lack of clinically meaningful response (less than 50% improvement in depressive symptoms) to at least two adequate antidepressant trials during the current episode, as recorded by the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ). An adequate trial requires sufficient dosage (within the recommended therapeutic range) and duration (at least 6 weeks). The current episode must involve at least one treatment failure.\n* A Hamilton Depression Rating Scale 17-item (HAMD-17) total score of ≥ 20 at both the screening and baseline visits.\n* The subject agrees to maintain their existing baseline antidepressant therapy regimen unchanged throughout the study period.\n* The patient and their legal guardian understand and voluntarily agree to participate in this study, are capable of adhering to the treatment protocol, and provide written informed consent.\n\nExclusion Criteria:\n\n* A current or prior diagnosis of any other DSM-5 mental disorder, including but not limited to: neurodevelopmental disorders, bipolar and related disorders, obsessive-compulsive and related disorders, schizophrenia spectrum and other psychotic disorders, substance-related and addictive disorders, or personality disorders.\n* A past medical history or current presence of clinically significant somatic diseases, such as severe or unstable cardiovascular, respiratory, digestive, endocrine, urinary, hematological, or nervous system diseases, or benign\u002Fmalignant tumors; or any condition deemed by the investigator to pose a potential risk to patient safety or their ability to fully participate in the study.\n* Any severe neurological disease or impairment, including but not limited to: any condition potentially associated with increased intracranial pressure, space-occupying brain lesions, cerebral infarction, intracranial hemorrhage, history of epileptic seizures or family history of epilepsy (except for those induced by ECT), cerebral aneurysm, Parkinson's disease, Huntington's disease, multiple sclerosis, or a history of severe head trauma with loss of consciousness; or any condition deemed by the investigator to pose a potential risk to patient safety or their ability to fully participate in the study.\n* Assessed by the investigator as being at significant risk of suicide, evidenced by: a \"Yes\" response to Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) in the \"Suicidal Ideation\" section of the Columbia-Suicide Severity Rating Scale (C-SSRS) within the past 6 months; OR a \"Yes\" response to any item in the \"Suicidal Behavior\" section of the C-SSRS (actual attempt, interrupted attempt, aborted attempt, preparatory acts or behavior) within the past 6 months; OR a score of ≥5 on Item 10 (Suicidal Thoughts) of the Montgomery-Åsberg Depression Rating Scale (MADRS).\n* Participation in other systematic neuromodulation therapies (e.g., MECT, rTMS, tDCS, VNS, DBS) within 3 months prior to screening, or participation in an interventional clinical trial within 1 month prior to screening.\n* Patients who have been non-responsive to a systematic course of MECT treatment.\n* Patients with a history of other psychosurgical procedures (including radiofrequency ablation, focused ultrasound, etc.).\n* A history of prior radiotherapy, chemotherapy, or immunotherapy, or a history of occupational exposure to radiation\u002Ftoxic substances.\n* Contraindications to Magnetic Resonance Imaging (MRI), including but not limited to: intracranial or bodily metallic implants, implanted pacemakers or cochlear implants, or claustrophobia.\n* Pregnant or lactating women.\n* Subjects of either gender who plan to become pregnant within the next 6 months or are unwilling to use effective contraception.\n* Subjects with a body weight exceeding 150 kg.\n* Any other condition considered by the investigator to make the subject unsuitable for participation in this study.",{"count":372,"type":23},9,[26],"This study is an clinical trial aimed at evaluating the effectiveness and safety of stereotactic radiotherapy for treatment-resistant depression",[376,377],"Treatment-Resistant Depression","Depressive Disorder",[379,380,381,382,383],"Treatment-Resistant depression","X-ray","subgenual anterior cingulate cortex","ZAP-X","stereotactic radiotherapy",{"date":385,"type":39},"2026-04-27",{"date":387,"type":39},"2026-01-26",{"date":389,"type":23},"2028-06",{"name":45,"class":46},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":130,"enrollmentInfo":398,"targetDuration":4,"studyType":24,"phases":400,"briefSummary":401,"conditions":402,"keywords":403,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":416},"100613186","phase-3-albumin-for-patients-with-acute-large-vessel-occlusive-stroke-undergoing-endovascular-therapy--2-100613186","NCT07263308","Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2","ARISE-2","Inclusion Criteria:\n\n1. Age between 18 and 80 years;\n2. Acute ischemic stroke with indications for endovascular treatment within 24 hours of onset;\n3. Anterior circulation acute ischemic stroke, with acute occlusion of the responsible vessel located in the intracranial segment of the internal carotid artery, or the M1 or M2 segment of the middle cerebral artery;\n4. National Institute of Health Stroke Scale (NIHSS) score \\>=6;\n5. Alberta Stroke Program Early CT Score (ASPECTS) \\>=3 points;\n6. Modified Rankin Scale (mRS) score ≤4 before onset of the disease;\n7. Written informed consent provided by the patients or their legal relatives.\n\nExclusion Criteria:\n\n1. Evidence of intracranial hemorrhage (intracerebral hematoma (ICH), subarachnoid hemorrhage (SAH), epidural hemorrhage, acute or chronic subdural hematoma (SDH)) on the baseline CT or MRI scan;\n2. History of congenital or acquired bleeding disorders, coagulation factor deficiency diseases, thrombocytopenic diseases, etc;\n3. Anticipated difficulty in completing endovascular treatment due to vascular tortuosity;\n4. Known severe allergy (more severe than skin rash) to contrast agents uncontrolled by medications;\n5. Pregnancy, breastfeeding;\n6. An episode or exacerbation of congestive heart failure from any cause in the past 6 months;\n7. History of heart valve disease complicated by congestive heart failure within the past 6 months;\n8. Cardiac surgery with thoracotomy (eg. coronary artery bypass grafting or valve replacement surgery) within the past 6 months;\n9. Acute myocardial infarction in the past 6 months;\n10. Signs or symptoms of acute myocardial infarction upon admission, including electrocardiographic findings;\n11. Elevated serum troponin concentration upon admission (\\>0.1 μg\u002FL) ;\n12. Acute arrhythmia (including any tachycardia or bradycardia) with hemodynamic instability (systolic blood pressure \\\u003C100 mm Hg) upon admission;\n13. Acute or chronic lung diseases requiring long-term or intermittent oxygen therapy;\n14. Findings on physical examination of any of the following abnormalities: (1) Jugular venous distension (jugular venous pulsation \\>4 cm above the sternal angle); (2) Resting tachycardia due to congestive heart failure (heart rate \\> 100 per\u002Fmin); (3) Third heart sound; (4) Abnormal hepatic jugular venous reflux; (5) Pitting edema of the lower extremities attributable to congestive heart failure or without apparent cause; (6) Rales in both lungs; (7) Or evidence of pulmonary edema, pleural effusion, or pulmonary vascular redistribution on chest X-ray;\n15. Severe chronic anemia (hemoglobin \\\u003C 75 g\u002FL);\n16. Known recent or current serum creatinine exceeding 1.5 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin;\n17. Refractory hypertension that is difficult to control by medication (defined as systolic blood pressure \\> 220 mmHg, or diastolic blood pressure \\> 110 mmHg);\n18. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is greater than 1.5 times the upper limit of the normal value.\n19. History of albumin allergy or known allergy to albumin;\n20. Patients with severe mental disorders or dementia who are unable to cooperate in completing informed consent and follow-up content;\n21. The expected survival time is less than 90 days (such as comorbidity with malignant tumor or severe systemic diseases etc.);\n22. Patients who have participated in other interventional clinical studies within 30 days before randomization or are currently participating in other interventional clinical studies.\n23. The investigator believes that the subject has other conditions making it unsuitable for participating in this study.",{"count":399,"type":23},1192,[258],"This study is a prospective, multicenter, open-label, randomized controlled clinical trial. The investigators will apply albumin to the reperfusion treatment of patients with acute ischemic stroke in the anterior circulation. This study aims to verify the efficacy and safety of albumin combined with endovascular treatment in patients with anterior circulation acute ischemic stroke.",[233],[404,405,233,406,407],"Albumin","Acute Large Vessel Occlusive Stroke","Endovascular Therapy","China","2026-04-12",{"date":410,"type":39},"2026-04-15",{"date":412,"type":39},"2025-12-18",{"date":414,"type":23},"2027-12-01",{"name":45,"class":46},12,{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":24,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":433,"leadSponsor":435,"locationsCount":4},"100633800","phase-3-safety-and-efficacy-of-remote-ischemic-conditioning-in-patients-with-acute-myocardial-injury-following-acute-ischemic-stroke-100633800","NCT07531394","Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic Stroke","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of sex;\n2. AIS confirmed by neuroimaging within 72 hours of symptom onset (or last known well time);\n3. Acute myocardial injury confirmed by serial measurements of plasma cardiac troponin (cTn) within 72 hours of symptom onset \\[19\\];\n4. Written informed consent provided by the participant or their legal authorized representative.\n\nExclusion Criteria:\n\n1. Pre-stroke mRS score ≥ 2;\n2. AIS patients receiving intravenous thrombolysis or endovascular thrombectomy;\n3. Definite history of coronary heart disease, severe valvular heart disease, arrhythmia, heart failure, cardiomyopathy, elevated cTn, and abnormal electrocardiogram (ECG) before onset;\n4. Suspicious cardiac-related symptoms (recurrent\u002Fpersistent chest pain\u002Fchest tightness\u002Fpalpitations, etc.) within 14 days before the index stroke;\n5. Any disorder that could potentially lead to elevated pre-stroke cTn: sepsis, acute kidney injury, rhabdomyolysis, major cardiac surgery or myocardial infarction, previous ischemic or hemorrhagic stroke, congestive heart failure, pulmonary embolism, deep vein thrombosis, endocarditis, severe anemia, thyroid dysfunction, Drug application, etc.;\n6. Patients who are planning for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) for the index AMI within 3 months;\n7. Severe liver or kidney dysfunction or malignant tumors;\n8. Uncontrolled hypertension (systolic blood pressure ≥ 200mmHg at enrollment despite medication);\n9. Any limb deformity, vascular or soft tissue injury, orthopedic trauma, or other conditions affecting the implementation of RIC;\n10. Pregnancy or lactation period;\n11. Patients with psychiatric disorders or other reasons unable to cooperate with treatment and follow-up.",{"count":424,"type":23},580,[258],"Introduction: The management of acute myocardial injury following acute ischemic stroke (AMI-AIS), a frequent complication that severely worsens prognosis, is challenging. Remote ischemic conditioning (RIC) has demonstrated therapeutic potential in separate cardiac and cerebrovascular diseases, and preliminary single-center evidence suggests its safety and efficacy in patients with acute ischemic stroke (AIS) complicating acute myocardial infarction. Therefore, we propose to conduct a multicenter, randomized controlled trial to definitively evaluate the safety and efficacy of RIC in patients with AMI-AIS.\n\nMethods: This is a multicenter, randomized, double-blind, sham-controlled trial of 580 participants with AMI-AIS. Participants will be randomized to receive either the RIC procedures or sham RIC procedures twice daily for 14 consecutive days. A 3-month follow-up will be conducted to assess the safety and efficacy of RIC in AMI-AIS patients. The primary study outcome is the incidence of major adverse cardio-cerebrovascular events (MACCEs). The secondary outcomes include mortality, neurological and cardiac function, cerebral infarct volume, and cerebral perfusion.",[428,429],"Ischemic Stroke, Acute","Myocardial Injury","2026-04-09",{"date":410,"type":39},{"date":318,"type":23},{"date":434,"type":23},"2028-12-01",{"name":45,"class":46},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":130,"enrollmentInfo":444,"targetDuration":4,"studyType":24,"phases":446,"briefSummary":447,"conditions":448,"keywords":451,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":460,"leadSponsor":461,"locationsCount":4},"100631029","development-and-usability-evaluation-of-a-knowledge-graph-based-symptom-management-system-for-patients-with-breast-cancer-undergoing-chemotherapy-100631029","NCT07495358","Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cancer Undergoing Chemotherapy","Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management Recommendation System for Patients With Breast Cancer Undergoing Chemotherapy","KG-SMR-BC","Inclusion Criteria:\n\n* Aged 18 to 80 years\n* Pathologically confirmed breast cancer\n* Stage I-III breast cancer\n* Planning to initiate or currently receiving neoadjuvant or adjuvant chemotherapy\n* Expected to continue chemotherapy during the study period and complete at least two treatment time points\u002Fcycles\n* Able and willing to provide informed consent\n* Able to complete basic smartphone operations and system tasks independently or with guidance from the research staff\n\nExclusion Criteria:\n\n* Recurrent or metastatic breast cancer (stage IV)\n* Significant cognitive impairment or communication barriers that preclude informed consent or completion of study procedures\n* Severe psychiatric disorders or unstable psychiatric symptoms that may interfere with study participation\n* Considered unsuitable for participation by the clinical or research team because of unstable medical condition or need for acute management",{"count":445,"type":23},30,[26],"Patients with breast cancer patients undergoing chemotherapy commonly experience multiple co-occurring symptoms that are dynamic, interrelated, and difficult to manage using conventional approaches. Existing symptom management strategies often fail to address the complexity and evolving nature of symptom experiences during treatment.\n\nThis study aims to develop a knowledge graph-based symptom management recommendation system for patients with breast cancer undergoing chemotherapy and to evaluate its usability and preliminary effectiveness among both patients and nurses. The system integrates evidence-based guidelines, clinical expertise, and patient-reported data to provide personalized recommendations for symptom management.\n\nIn this study, patients will use the system to report symptoms and receive tailored management recommendations, while nurses will use it to support clinical decision-making and symptom management. Usability, acceptability, and user experience will be assessed for both patients and nurses, and changes in symptom burden and management outcomes will be evaluated.\n\nThe findings are expected to inform the feasibility and optimization of multi-user digital health interventions for comprehensive symptom management in oncology care.",[449,450],"Breast Neoplasms","Syndrome",[452,453,454,455],"breast cancer","symptom management","chemotherapy","recommender system","2026-03-27",{"date":458,"type":39},"2026-04-01",{"date":410,"type":23},{"date":302,"type":23},{"name":45,"class":46},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":19,"minAge":468,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":24,"phases":471,"briefSummary":472,"conditions":473,"keywords":475,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":246},"100611148","phase-3-suraxavir-marboxil-and-oseltamivir-for-influenza-prophylaxis-under-a-hospital-based-setting-100611148","NCT07236814","Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting","1.Inclusion Criteria:\n\n(1)Inclusion Criteria for Index Cases:\n\n① Patients hospitalized at a participating medical institution.\n\n* The subject and\u002For their legal guardian agrees to participate in this clinical study, has signed the informed consent form, and is able to comply with the protocol requirements for follow-up and complete all study procedures and assessments.\n\n  * Age ≥ 2 years.\n\n    * Positive for influenza virus as determined by a Rapid Antigen Test (RAT) or Nucleic Acid Amplification Test (NAAT) on a respiratory specimen (e.g., oropharyngeal swab, nasopharyngeal swab, sputum, or bronchoalveolar lavage fluid).\n\n      (2) Inclusion Criteria for Room Contacts:\n\n      ① Patients hospitalized at a participating medical institution.\n* The subject and\u002For their legal guardian agrees to participate in this clinical study, has signed the informed consent form, and is able to comply with the protocol requirements for follow-up and complete all study procedures and assessments.\n\n  ③ Age ≥ 12 years.\n  * Expected to remain hospitalized for ≥ 72 hours.\n\n    * Shares a room with at least one hospitalized index case who has been confirmed with influenza virus infection by RAT or NAAT on a respiratory specimen within the last 120 hours and developed influenza-related symptoms within the last 120 hours, and is expected to share the same room for ≥ 24 hours.\n\n      ⑥ Negative for influenza virus as determined by a Nucleic Acid Amplification Test (NAAT) on a throat swab collected on Day 1.\n\n      3.Exclusion Criteria\n\n      (1) Index Cases There are no exclusion criteria for index cases. (2) Exclusion Criteria for Room Contacts:\n      * Room contacts with a known allergy to the active ingredients or excipients of the investigational drugs.\n* Room contacts who have been diagnosed with or have had an influenza virus infection in the past 12 weeks.\n\n  * Use of any anti-influenza antiviral drugs within 2 weeks prior to screening, including: neuraminidase inhibitors, polymerase inhibitors, hemagglutinin inhibitors, and M2 ion channel blockers (e.g., Oseltamivir, Zanamivir, Peramivir, Favipiravir, Arbidol, Baloxavir Marboxil, Amantadine, or Rimantadine, or other anti-influenza drugs approved by the NMPA).\n\n    * Known to be pregnant or breastfeeding. (Subjects who suspect they may be pregnant must report this to the investigator, who will confirm with a pregnancy test).\n\n      * History of fever (axillary temperature ≥ 37.3°C) within 72 hours prior to screening.\n\n        * Child-Pugh class B or C, or an eGFR ≤ 60 mL·min-¹·(1.73 m²)-¹. ⑦ Any subject deemed unsuitable for participation in the study by the investigator.","12 Years",{"count":470,"type":23},384,[258],"This study aims to evaluate the efficacy of antiviral prophylaxis in preventing in-hospital influenza transmission. We will enroll hospitalized patients with confirmed influenza (index cases) and their uninfected roommates (room contacts). These room contacts will be randomized in a 1:1:1 ratio to one of three prophylactic groups: placebo, suraxavir marboxil, or oseltamivir. The primary outcome will be the rate of influenza infection among the room contacts, which will be monitored to determine the effectiveness of the interventions.",[474],"Influenza",[476,477,478],"influenza","suraxavir marboxil","oseltamivir","2026-03-19",{"date":481,"type":39},"2026-03-23",{"date":483,"type":39},"2025-11-28",{"date":485,"type":23},"2027-03-06",{"name":45,"class":46},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":18,"sex":19,"minAge":494,"maxAge":495,"enrollmentInfo":496,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":498,"conditions":499,"keywords":501,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":47},"100440807","the-diagnostic-cut-off-value-of-core-biomarkers-of-alzheimers-disease-100440807","NCT05020106","The Diagnostic Cut-off Value of Core Biomarkers of Alzheimer's Disease","Study on the Diagnostic Cut-off Value of Core Biomarkers in Cerebrospinal Fluid and Blood of Alzheimer's Disease","Inclusion Criteria:\n\n* Aged 55-75. Written informed consent obtained from participant or legal guardian prior to any study-related procedures. The diagnosis of AD is made using the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria. The diagnosis of aMCI is assigned according to 2004 Petersen criteria. As for non-AD dementia, the McKeith criteria are used for DLB, the revised diagnostic criteria proposed by the International bvFTD Criteria Consortium for behavioral variant FTD, the Gorno-Tempini criteria for the semantic variant FTD or non-fluent aphasia, the Movement Disorder Society Task Force criteria for PDD, the vascular behavioral and cognitive disorders (Vas-Cog) criteria for VaD, the Armstrong's criteria for CBD, the CDC's diagnostic criteria for CJD, etc. In addition, normal cognition is supported by MMSE, CDR and other cognitive function scales.\n\nExclusion Criteria:\n\n* Other medical or psychiatric illness. No one can serve as an informant. Refused to complete a cognitive test and provide biospecimen.","55 Years","75 Years",{"count":497,"type":23},3200,"The participant in this study includes Alzheimer's disease (AD including familial AD and sporadic AD) patients, amnestic mild cognitive impairment (aMCI) patients, non-AD dementia patients and cognitively normal control.\n\nThe purpose of this study is to establish the best cut-off value of cerebrospinal fluid (CSF) and blood β-amyloid (Aβ) 42\u002F40, total tau (t-tau) , phosphorylated tau ,inflammatory factors, etc. in diagnosis of Alzheimer's disease (AD).",[500],"Alzheimer's Disease",[502],"Alzheimer's disease",{"date":481,"type":39},{"date":505,"type":39},"2018-09-01",{"date":507,"type":23},"2027-09-01",{"name":45,"class":46},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":18,"sex":19,"minAge":494,"maxAge":495,"enrollmentInfo":516,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":518,"conditions":519,"keywords":520,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":521,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":525,"locationsCount":47},"100427749","detection-of-alzheimers-disease-ad-related-seeds-for-ad-diagnosis-100427749","NCT04850053","Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis","Detection of Alzheimer's Disease (AD)-Related Seeds as Biomarkers for Accurate Diagnosis of AD（AD-seeds-detector）","Inclusion Criteria:\n\n* Aged 55-75. Written informed consent obtained from participant or legal guardian prior to any study-related procedures. The diagnosis of AD is made using the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria. As for non-AD dementia, the McKeith criteria are used for DLB,the revised diagnostic criteria proposed by the International behavioral variant (bvFTD) Criteria Consortium for bvFTD,the Gorno-Tempini criteria for the semantic variant FTD or non-fluent aphasia, the Movement Disorder Society Task Force criteria for PDD, the vascular behavioral and cognitive disorders (Vas-Cog) criteria for VaD, the Armstrong's criteria for CBD, the CDC's diagnostic criteria for CJD, etc. In addition, normal cognition is supported by MMSE, CDR and other cognitive function scales.\n\nExclusion Criteria:\n\n* Other medical or psychiatric illness. No one can serve as an informant. Refused to complete a cognitive test and provide biospecimen.",{"count":517,"type":23},1500,"The study will investigate the biomarkers of Aβ and Tau seeds in plasma detected by Alzheimer's disease (AD) related seeds quantitative detector (AD-seeds-detector), and their sensitivity and specificity in diagnosing AD, compared with those from age-matched cognitively normal controls, and those with other types of dementia.\n\nTo perform a high throughput analysis of the amount of Aβ and Tau seeds, the investigators have developed an AD-seeds-detector, in which a fluorescence microplate reader was combined with an oscillating mixer or water-bath-type ultrasonicator.",[500],[502],{"date":481,"type":39},{"date":523,"type":39},"2020-08-26",{"date":201,"type":23},{"name":45,"class":46},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":535,"conditions":536,"keywords":538,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":47},"100406662","study-on-biomarkers-for-early-diagnosis-of-alzheimers-disease-100406662","NCT04575337","Study on Biomarkers for Early Diagnosis of Alzheimer's Disease","Study on Body Fluid, Gene and Neuroimaging Biomarkers for Early Diagnosis of Alzheimer's Disease","Inclusion Criteria:\n\n* Written informed consent obtained from participant or legal guardian prior to any study-related procedures.\n* Aged 18 (inclusive) or older.\n* Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS- ADRDA) or National Institute on Aging and the Alzheimer's Assocation (NIA-AA) criteria. A diagnosis of mild cognitive impairment (MCI) is assigned according to Petersen criteria. A diagnosis of pre-MCI group is assigned by β-Amyloid positive or APOE ε4 carrier or complains of cognitive impairment, but not up to MCI or cognitive impairment. Normal cognitive function assessed\u002Fevaluated by MMSE, CDR and other cognitive function scales.\n* Follow up 5 years and collect the information.\n\nExclusion Criteria:\n\n* Under age 18.\n* Medical or psychiatric illness that would interfere in completing initial and follow-up visits.\n* No one can serve as a study informant.\n* With current or past neurological or psychiatric illnesses such as schizophrenia, epilepsy, brain tumors, severe head trauma and other diseases which can induce dementia.\n* Refused to complete a cognitive test and provide biospecimen.\n* With history of alcohol or drug abuse.",{"count":534,"type":23},6000,"The project of Bio-AD is a population- based cohort study among the elderly in China.\n\nThe project includes not only Alzheimer's disease (AD including familial AD and sporadic AD), but also other clinical stage of AD, as well as elderly people with normal cognitive function.\n\nThe project will collect, detect and screen the special biomarkers at different clinical stage of AD based on body fluid, gene and brain image. The standard and consistent assessment protocols are employed to obtain clinical, cognitive, genetic, neuroimaging and biospecimen data.\n\nThe purpose of this project is to establish a panel of biomarkers which could be used to diagnose AD at the early stage, and to establish a risk prediction models for AD to predict the 5-years risk of the onset and progression of AD among elderly population in China.",[537],"Alzheimer Disease",[537],{"date":481,"type":39},{"date":541,"type":39},"2020-05-28",{"date":543,"type":23},"2027-06-30",{"name":45,"class":46},{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":551,"eligibilityCriteria":552,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":553,"targetDuration":555,"studyType":83,"phases":4,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":564,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":570},"100335879","china-cognition-and-aging-study-100335879","NCT03653156","China Cognition and Aging Study","China Cognition and Aging Study: a Multi-center, National-wide, Longitudinal Study in China","COAST","Community population: age ≥ 55 years, male or female, with consent to participant the study.\n\nHospital population: subjects are all over 18 years old. Through clinical evaluation, neuropsychological test, imaging examination, blood and cerebrospinal fluid examination, etc, we will comprehensively evaluate the cognitive function and various test measures.\n\n(1) MCI and its subtypes\n\nInclusion criteria:\n\n1. Diagnosis according to 2004 Peterson's MCI criteria.\n2. CDR = 0.5.\n3. Memory loss is prominent, and may also be with other cognitive domain dysfunction.\n4. Insidious onset, slow progress.\n5. Not reaching the level of dementia.\n\nExclusion criteria:\n\n1. With history of stroke and a neurological focal sign, the imaging findings are consistent with cerebral small vessal disease (Fazekas score ≥ 2 points).\n2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).\n3. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).\n4. Mental and neurodevelopmental retardation.\n5. Contraindications to MRI.\n6. Suffering from a disease that cannot be combined with cognitive examination.\n7. Refuse to draw blood.\n8. Refuse to sign the informed consent at baseline\n\n(2) Sporadic Alzheimer's disease (SAD)\n\nInclusion criteria:\n\n1. Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R). The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) or National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.\n2. Subjects and their informed persons can complete relevant and follow- up examinations.\n3. Subjects or their authorized legal guardians sign the informed consent.\n\nExclusion criteria:\n\n1. With a family history of dementia.\n2. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).\n3. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).\n4. Mental and neurodevelopmental retardation.\n5. Contraindications to MRI.\n6. Suffering from a disease that cannot be combined with cognitive examination.\n7. Refuse to draw blood.\n8. Refuse to sign the informed consent at baseline\n\n(3) Familial Alzheimer's disease (FAD)\n\nInclusion criteria:\n\n1. Written informed consent obtained from participant or legal guardian prior to any study-related procedures.\n2. Members in FAD pedigree (FAD is defined as at least two first- degree relatives suffer from AD).\n3. Aged 18 (inclusive) or older.\n4. At least two persons who can provide reliable information for the study. Note: Dementia is diagnosed according to the criteria described by DSM-IV-R. The diagnosis of AD is made using NINCDS-ADRDA or NIA-AA criteria. A diagnosis of MCI is assigned according to Petersen criteria.\n\nExclusion criteria:\n\n1. Dementia caused by other factors such as depression, other psychiatric illnesses, thyroid dysfunction, encephalitis, multiple sclerosis, brain trauma, brain tumor, syphilis, acquired immunodeficiency syndrome (AIDS), Creutzfeldt-Jakob disease and other types of dementias such as vascular dementia (VaD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and Parkinson's disease dementia (PDD).\n2. MRI and laboratory tests do not support or rule out a diagnosis of AD.\n3. Severe circulatory, respiratory, urinary, digestive, hematopoietic diseases (such as unstable angina, uncontrollable asthma, active gastric bleeding) and cancer.\n4. Participant has severe psychiatric illness or severe dementia that would interfere in completing initial and follow-up clinical assessments.\n5. With history of alcohol or drug abuse.\n6. Pregnant or lactating women.\n7. No reliable insiders.\n8. Refuse to sign the informed consent at baseline.\n\n(4) Vascular dementia (VaD)\n\nInclusion criteria:\n\nDiagnosis for probable VaD according to NINDS-AIREN diagnostic criteria.\n\nMRI inclusion criteria:\n\nAll patients who meet clinical inclusion criteria should accept MRI scans which include an assessment of hippocampal volume.\n\n1. multiple (≥3) supratentorial subcortical small infarcts (3-20 mm in diameter) with or without any degree of white matter lesion (WML); or moderate to severe WML (Fazekas score ≥ 2), with or without small infarction; or ≥ 1 subcortical small infarct in key regions, such as caudate nucleus, globus pallidus, or thalamus.\n2. no cortical and watershed infarction, hemorrhage, hydrocephalus, or WML with specific causes (such as multiple sclerosis).\n3. no hippocampus or entorhinal cortex atrophy (MTA score = 0 point).\n\nExclusion criteria:\n\n1. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).\n2. Other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).\n3. With a history of mental illness or those with congenital mental retardation.\n4. Suffering from a disease that cannot be combined with a cognitive examination.\n5. Contraindications to MRI.\n6. Refuse to draw blood.\n7. Refuse to sign informed consent.\n\n(5) Normal control\n\nInclusion criteria:\n\n1. Aged 18 (inclusive) or above.\n2. Normal MMSE and MoCA evaluations. MMSE\\>19 points for illiteracy, \\>24 points for those educated less than 7 years, \\>27 points for those educated equal to or more than 7 years. MoCA\\>13 points for illiteracy, \\>19 points for those educated less than 7 years, \\>24 points for those educated equal to or more than 7 years.\n\nExclusion criteria:\n\n1. Subjects with abnormal MMSE or MoCA scores.\n2. Subjects with a history of cerebral infarction, traumatic brain injury or related manifestations in MRI.\n3. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.).\n4. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.).\n5. Mental and neurodevelopmental retardation.\n6. Suffering from a disease that cannot be combined with a cognitive examination.\n7. Contraindications to MRI.\n8. Refuse to draw blood.\n9. Refuse to sign the informed consent at baseline.",{"count":554,"type":23},100000,"30 Years","The aim of this study is to establish and perfect the China Cognition and Aging Study (China COAST) cohort, to clarify the epidemiology, influencing factors, genetic characteristics, pathogenesis, disease characteristics and diagnosis and treatment status of dementia and its subtypes in China. It is of great significance to establish a relatively comprehensive national database of cognitive disorders, improve the clinical diagnosis and treatment level of cognitive disorders, and formulate prevention and treatment strategies for dementia. The primary aims of China COAST are as follows:\n\n1. To use the prospective cohort to establish a large database research platform, so as to provide comprehensive epidemiological data, clinical and neuropsychological evaluation data, biological samples, and laboratory tests and imaging data.\n2. To update the prevalence and incidence rate of dementia and its subtypes every 2-3 years, and clarify the conversion pattern from normal elderly to MCI and from MCI to dementia.\n3. To explore the known or unknown protective and risk factors of dementia and its major subtypes (AD, VaD, other dementia).\n4. To discover new pathogenic genes and susceptible genes of dementia and its major subtypes (AD and VaD), as well as new mutation sites of known pathogenic genes. To study the genetic variation, mutation and polymorphism of PSEN1, PSEN2, APP and APOE genes in dementia patients, and to understand their distribution and roles in the pathogenesis.\n5. To study the biomarkers (body fluid, genetics, imaging) with diagnostic value of MCI, AD (sporadic and familial) and VaD, to define their cut-off values, and to establish prediction models.\n6. To study the diagnostic criteria of cognitive normal, MCI, dementia and their subtypes (clinical and molecular subtypes) in the cohort, and to make psychological assessment scales with high sensitivity and specificity, and in line with the characteristics of Chinese people.\n7. To find potentially modifiable risk factors for dementia and to study the prevention and intervention effect of non-pharmacological treatment on APOE ε4 carriers, MCI and AD or other dementia patients，which included improvements in education, nutrition, health care, and lifestyle changes. This needs a long time follow-up.\n8. To explore the relationship between dementia as well as its major subtype AD and cerebral and systemetic circulatory disorders (for example, mixed dmentia), as well as potential therapeutic strategies.\n9. To carry out investigation and researches about dementia related education, improve the awareness of dementia, and strengthen the management of dementia.\n10. To investigate the level of stigma and discrimination and its influencing factors in patients with Alzheimer's disease and their caregivers.",[558,559,560,561,562,563],"Mild Cognitive Impairment(MCI)","Alzheimer Disease, Late Onset","Familial Alzheimer Disease (FAD)","Vascular Dementia (VaD)","Normal Control","Non-Alzheimer Degenerative Dementia",{"date":481,"type":39},{"date":566,"type":39},"2000-01-01",{"date":568,"type":23},"2038-01-01",{"name":45,"class":46},65,{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":579,"targetDuration":555,"studyType":83,"phases":4,"briefSummary":581,"conditions":582,"keywords":583,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":588,"locationsCount":570},"100336231","the-chinese-familial-alzheimers-network-100336231","NCT03657732","The Chinese Familial Alzheimer's Network","A Multi-center Longitudinal Cohort Study of Familial Alzheimer's Disease in China","CFAN","Familial Alzheimer's disease group\n\nInclusion criteria:\n\n1. Written informed consent obtained from the participant or a legal guardian prior to any study-related procedures;\n2. At least two first-degree relatives in a family have AD (clinically or by testing)，and at least 3 out of 2 generations are patients;\n3. At least one family member with normal cognitive function (the age should be greater than the average age of onset of the family);\n4. Pedigrees carrying FAD pathogenic genes (APP\u002FPSEN1\u002FPSEN2);\n5. People in this family \\>18 years old can be recruited;\n6. Participant is cognitively normal or demented but not reaching bedridden level;\n7. Participants are able to provide two reliable informants who can provide clinical information;\n8. Dementia is diagnosed according to the criteria described by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-R );\n9. The diagnosis of AD is made using the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA ) or National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria ;\n10. The diagnosis of MCI is made according to Petersen criteria and the classification is according to the method of Lopez et al.\n\nExclusion criteria:\n\n1. Dementia caused by other factors such as depression, other psychiatric illnesses, thyroid dysfunction, encephalitis, multiple sclerosis, brain trauma, brain tumor, syphilis, acquired immunodeficiency syndrome (AIDS), Creutzfeldt-Jakob disease and other types of dementias such as vascular dementia (VaD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and Parkinson's dementia (PDD)；\n2. MRI and laboratory tests do not support or rule out a diagnosis of AD；\n3. Severe circulatory, respiratory, urinary, digestive, hematopoietic diseases (such as unstable angina, uncontrollable asthma, active gastric bleeding) and cancer；\n4. Participant has severe psychiatric illness or severe dementia that would interfere in completing initial and follow-up clinical assessments；\n5. Participant has a history of alcoholism or drug abuse；\n6. Pregnant or lactating women；\n7. No reliable informant；\n8. Lumbar puncture exclusion criteria：coagulation disorders or platelet counts \\\u003C 100,000 cells\u002FμL, lumbar surgery within the last 6 months prior to lumbar puncture that interferes with anatomy of the inter-vertebral spaces, History of chronic or repeated CSF leakage following previous LP(s);\n9. MRI Exclusion Criteria: electronic and magnetic metal implants such as pacemakers, artificial heart valve, metal prosthesis, metal joint, etc.; metallic foreign body in the eye; aneurysm clips in the brain.\n\nNormal control group\n\nInclusion criteria:\n\n1. Aged 18 (inclusive) or above;\n2. Normal MMSE and MoCA evaluations. MMSE\\>19 points for illiteracy, \\>24 points for those educated less than 7 years, \\>27 points for those educated equal to or more than 7 years. MoCA\\>13 points for illiteracy, \\>19 points for those educated less than 7 years, \\>24 points for those educated equal to or more than 7 years.\n\nExclusion criteria:\n\n1. Subjects with abnormal MMSE or MoCA scores;\n2. Subjects with a history of cerebral infarction, traumatic brain injury or related manifestations in MRI;\n3. Other neurological diseases that can cause brain dysfunction (such as depression, brain tumor, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal intracranial pressure hydrocephalus, etc.);\n4. Other systemic diseases that can cause cognitive impairment (such as liver, renal and thyroid insufficiency, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);\n5. Mental and neurodevelopmental retardation;\n6. Suffering from a disease that cannot be combined with a cognitive examination;\n7. Contraindications to MRI;\n8. Refuse to draw blood;\n9. Refuse to sign the informed consent at baseline.",{"count":580,"type":23},40000,"This research will establish and continuously improve the FAD research network in conjunction with multi-center institutions nationwide. By collecting information on the family's demography, genetics, neuropsychology, neuroimaging, biomarkers and other information, we can understand the current FAD population in China, clarify the genetic characteristics, pathogenesis, disease characteristics and diagnosis and treatment status of AD in China; which will lay the foundation for ameliorating clinical diagnosis and treatment, establishing a Chinese FAD clinical database and an international cooperative research platform.\n\n1. To set up a multi-center, nationwide FAD research network and database platform in China\n2. To clarify the epidemiological characteristics of FAD in China.\n3. To clarify the genetic characteristics of FAD in China.\n4. To clarify the clinical characteristics and disease development laws of FAD.\n5. To discover and verify the early diagnosis biomarkers of AD.\n6. To establish a genetic counseling model.",[537,560],[500],{"date":481,"type":39},{"date":586,"type":39},"2005-01-10",{"date":568,"type":23},{"name":45,"class":46},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":24,"phases":598,"briefSummary":599,"conditions":600,"keywords":602,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":47},"100629241","effect-of-tngs-on-cap-patients-with-initial-treatment-failure-100629241","NCT07472114","Effect of tNGS on CAP Patients With Initial Treatment Failure","Impact of Targeted Next-generation Sequencing on Hospitalized Patients With Community-acquired Pneumonia and Initial Treatment Failure","Inclusion Criteria:\n\n* Adults (age ≥ 18 years)\n* Diagnosed of community-acquired pneumonia\n* Initial treatment failure\n\nExclusion Criteria:\n\n* tNGS or mNGS already performed on respiratory samples during the current illness\n* Suspected lung abscess or empyema\n* Cerebral infarction within the past three months\n* Dysphagia\n* Nasopharyngeal carcinoma currently receiving radiotherapy\n* Tracheostomy\n* Long-term bedridden patients (ADL score ≤ 60)\n* Pathogens identified within the past 7 days that adequately explain the current clinical presentation\n* Bronchiectasis with large amounts of sputum and documented bacterial detection within the past six months\n* Inability to obtain eligible respiratory samples\n* CURB-65 score ≤ 1\n* Expected discharge or death within 48 hours",{"count":597,"type":23},524,[26],"This is a multicenter, randomized controlled trial designed to evaluate the impact of tNGS in patients with community-acquired pneumonia who experience initial treatment failure.",[601],"Community Acquired Pneumonia (CAP)",[603,604,605,606],"targeted next generation sequencing","community acquired pneumonia","RCT","initial treatment failure","2026-03-12",{"date":609,"type":39},"2026-03-16",{"date":611,"type":23},"2026-04-10",{"date":613,"type":23},"2028-02-28",{"name":45,"class":46},""]